19th Sep 2006 07:00
For immediate release 19 September 2006 LIDCO GROUP PLC ("LiDCO" or "the Company") Southampton University Hospital Extends Monitor Contract LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, announcesthe purchase of an additional 6 LiDCOplus Monitors by Southampton UniversityHospital Trust. The contract is in excess of ‚£80K and delivery was made on 8September 2006.Southampton University Hospital Trust (the "Trust") now has a total of 14LiDCOplus monitors in use across the hospital in a variety of differentclinical locations including: intensive care, post cardiac surgery and neurointensive care. During the evaluation process, competing technologies wereevaluated across several criteria including clinical utility and costeffectiveness. LiDCO scored highly in all areas. Having evaluated all of thealternative devices on market in the UK, LiDCO was regarded as the best andmost accurate and has allowed the hospital to further phase out the use of theolder invasive catheter based product.Dr Mike Herbertson Consultant Cardiac Anesthetist said "Southampton UniversityHospital Trust have expanded their facility for the care of patients with heartdisease as a result of a ‚£60 million investment from NHS funds. An importantpart of the expansion has been the creation of a new critical care complex.Within the critical care complex the Trust has purchased new equipment toimprove care for patients with heart disease. A central part of this newequipment has been the purchase of six state of the art monitors from LiDCOGroup Plc. The LiDCOplus monitors we have purchased provide crucial informationfor the care of patients after heart surgery. We have used these monitors forsome of our patients after heart surgery over the last few years. As a resultof this purchase we plan to use these monitors as a standard part of the careof all patients after heart surgery. We expect the information we see fromthese monitors will allow us to further improve the outcomes for our cardiacsurgery patients."Commenting on this announcement, Terry O'Brien, Chief Executive of LiDCO, said:"We are delighted that Southampton Cardiac unit has chosen our technology asits minimally invasive hemodynamic monitor of choice. This is particularlyrewarding as it follows on from our technology being used in Southampton'sGeneral and Neuro intensive care units. We look forward very much to workingwith the doctors and nursing and technical staff there to ensure a smoothimplementation and use of our technology in order to continue to enhancepatient care. We are grateful to the staff and hospital trust management forthe faith they have in our company and technology. The progressive and wideradoption by the Trust and the NHS generally of LiDCO's minimally invasivemonitoring technology is driven by a desire to continually improve clinical andsurgical outcomes." LiDCO will announce its interim results for the six months to 31 July 2006 on18 October 2006. ---Ends--- For further information please contact:LiDCO Group Plc Tel: +44 (0)20 7749 1500 Terry O'Brien (CEO) Hugh McGarel-Groves (FD) Financial PR: Buchanan Communications Tel: +44 (0)20 7466 5000 Tim Anderson, James Strong Notes for editorsAbout LiDCO Group PlcLiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Departmentof Applied Physiology based at St Thomas' Hospital, London.The Company's manufacturing facility is in London N1, UK and its products are:LiDCOplus and PulseCO monitors: computer-based platforms for displaying andmanagement of a range of real-time, continuous hemodynamic parameters includingcardiac output, oxygen delivery and fluid volume;LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accuratelydetermine cardiac output in a minimally-invasive manner.Distribution Network:The Company has now achieved registration of its products in 14 markets inEurope, together with the USA, Brazil and Japan. It sells direct in the USAand UK, and elsewhere through a worldwide network of specialty critical caredistributors.ENDLIDCO GROUP PLCRelated Shares:
LID.L